Home>>Signaling Pathways>> Chromatin/Epigenetics>> HIF>>Daprodustat(GSK1278863)

Daprodustat(GSK1278863) Sale

(Synonyms: 达普司他,GSK1278863) 目录号 : GC16647

A HIF-PH1, -2, and -3 inhibitor

Daprodustat(GSK1278863) Chemical Structure

Cas No.:960539-70-2

规格 价格 库存 购买数量
5mg
¥704.00
现货
10mg
¥1,071.00
现货
50mg
¥3,381.00
现货
100mg
¥5,261.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Daprodustat (GSK1278863) is a HIF-prolyl hydroxylase inhibitor.

Hypoxia stimulates erythropoietin (EPO) release through accumulation of hypoxia-inducible factor 1α (HIF-1α), resulting in an increase of erythrocyte production by the bone marrow. HIF-prolyl hydroxylase inhibitors have been used to selectively activate the PHD-signaling pathway, leading to the stabilization of HIFα subunits, which can affect the transcription of HIF-responsive genes.

In vitro: In-vitro biotransformation data indicated that GSK1278863 was primarily metabolized by CYP2C8 [1].

In vivo: Currently, there is no animal in vivo data published.

Clinical trial: Previous study found that in both Japanese and Caucasian subjects GSK1278863 showed dose-proportional increases in AUCinf, with a 1.3-1.5-fold higher exposure seen in Japanese relative to Caucasians. Such exposure difference could be mainly explained by the observed differences in body weights. Statistically significant increases in erythropoietin, vascular endothelial growth factor (VEGF) and reticulocyte counts were observed in Japanese subjects as compared to placebo. In Caucasians, erythropoietin and VEGF levels were increased in response to the 100 mg dose. Moreover, drug-related adverse events, sucha as headache and abdominal pain, were reported in three Japanese subjects, whereas, headache was reported in three Caucasians [1]. A 28-day, phase 2A, randomized trial showed that GSK1278863 induced an effective EPO response and stimulated non-EPO mechanisms for erythropoiesis in anemic non-dialysis-dependent and dialysis-dependent patients with CKD [2].

References:
[1] Hara K,Takahashi N,Wakamatsu A,Caltabiano S.  Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet.2015 Dec;30(6):410-8.
[2] Brigandi RA,Johnson B,Oei C,et al.  A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. Am J Kidney Dis.2016 Jun;67(6):861-71.

Chemical Properties

Cas No. 960539-70-2 SDF
别名 达普司他,GSK1278863
化学名 2-(1,3-dicyclohexyl-2,4,6-trioxohexahydropyrimidine-5-carboxamido)acetic acid
Canonical SMILES O=C(O)CNC(C(C(N1C2CCCCC2)=O)C(N(C1=O)C3CCCCC3)=O)=O
分子式 C19H27N3O6 分子量 393.43
溶解度 ≥ 7.86mg/mL in DMSO with gentle warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.5417 mL 12.7087 mL 25.4175 mL
5 mM 0.5083 mL 2.5417 mL 5.0835 mL
10 mM 0.2542 mL 1.2709 mL 2.5417 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置